AU2013202364B2 - Control of coleopteran insect pests - Google Patents

Abstract

CONTROL OF COLEOPTERAN INSECT PESTS Improved compositions and methods for controlling coleopteran pests are disclosed. In particular, novel combinations of insecticidal proteins having improved toxicity to coleopteran insect pests such as corn rootworm are provided. Further, a method of killing or controlling coleopteran insect pests using the compositions of the invention is disclosed. -IkD Drw-blkl--\DC\ f-7A- 1 I-O - 2-Al/1-

Description

WO 2012/006271 PCT/US2011/042932 CONTROL OF COLEOPTERAN INSECT PESTS FIELD OF THE INVENTION [0001] The present invention relates generally to the control of pests that cause damage to crop plants by their feeding activities, and more particularly to the control of coleopteran pests by compositions comprising synergistic levels of a coleopteran-active protein toxin and a lepidopteran-active protein toxin. The invention further relates to the compositions and methods employing such compositions comprising the protein toxins. BACKGROUND [0002] Coleopteran insects are considered some of the most important pests to crop plants. For example, species of corn rootworm are the most destructive corn pests causing an estimated loss of over $1 billion annually. Important corn rootworm pest species include Diabrotica virgifera virgifera, the western corn rootworm; D. longicornis barberi, the northern corn rootworm, D. undecimpunctata howardi, the southern corn rootworm, and D. virgifera zeae, the Mexican corn rootworm. Colorado potato beetle (CPB; Leptinotarsa decemlineata), is another example of a coleopteran insect which is a serious pest of potato, tomato and eggplant world-wide. [0003] Coleopteran pests are mainly controlled by intensive applications of chemical pesticides, which are active through inhibition of insect growth, prevention of insect feeding or reproduction, or cause death. Good insect control can thus be reached, but these chemicals can sometimes also affect other, beneficial insects. Another problem resulting from the wide use of chemical pesticides is the appearance of resistant insect strains. This has been partially alleviated by various resistance management practices, but there is an increasing need for alternative pest control agents. [00041 Bacillus thuringiensis (Bt) Cry proteins (also called S-endotoxins) are proteins that form a crystalline matrix in Bacillus that are known to possess insecticidal activity when ingested by certain insects. Over 180 holotype Cry proteins in 58 families have been 1 WO 2012/006271 PCT/US2011/042932 identified and named. The various Cry proteins have been classified based upon their spectrum of activity and sequence homology. Prior to 1990, the major classes were defined by their spectrum of activity (Hofte and Whitely, 1989, Microbiol. Rev. 53:242-255), but more recently a new nomenclature was developed which systematically classifies the Cry proteins based on amino acid sequence homology rather than insect target specificities (Crickmore et al. 1998, Microbiol. Molec. Biol. Rev. 62:807-813). [00051 Genes coding for Cry proteins have been isolated and their expression in crop plants have been shown to provide another tool for the control of economically important insect pests. Such transgenic plants expressing the Cry proteins have been commercialized, allowing farmers to reduce or augment applications of chemical insect control agents. Coleopteran-active Cry proteins useful in transgenic plants include, for example, Cry3A, Cry3B and the Cry34/Cry35 complex. Examples of lepidopteran-active Cry proteins that have been expressed in transgenic plants include, for example, Cry1A (e.g. Cry 1Aa, Cry 1Ab, Cry1Ac), Cry1B, Cry1F and Cry2, among others. [0006] Another family of insecticidal proteins produced by Bacillus species during the vegetative stage of growth (vegetative insecticidal proteins (Vip)) has also been identified. U.S. Patents 5,877,012, 6,107,279, and 6,137,033, herein incorporated by reference, describe a new class of insecticidal proteins called Vip3. Other disclosures, including WO 98/18932, WO 98/33991, WO 98/00546, and WO 99/57282, have also identified homologues of the Vip3 class of proteins. Vip3 coding sequences encode approximately 88 kDa proteins that possess insecticidal activity against a wide spectrum of lepidopteran pests, including, but not limited to, black cutworm (BCW, Agrotis ipsilon), fall armyworm (FAW, Spodoptera frugiperda), tobacco budworm (TBW, Heliothis virescens), sugarcane borer, (SCB, Diatraea saccharalis), lesser cornstalk borer (LCB, Elasmopalpus lignosellus), and corn earworm (CEW, Helicoverpa zea), and when expressed in transgenic plants, for example corn (Zea mays), confer protection to the plant from insect feeding damage. [0007] There is an ongoing need for compositions and methods for using such compositions having insecticidal activity, for instance for use in crop protection or insect-mediated disease control. Novel compositions are required to overcome the problem of resistance to existing insecticides or to prevent the development of resistance to existing transgenic plant approaches. Ideally such compositions have a high toxicity and are effective when ingested 2 WO 2012/006271 PCT/US2011/042932 orally by the target pest. Thus any invention which provided compositions in which any of these properties was enhanced would represent a step forward in the art. SUMMARY [00081 The present invention provides improved compositions and methods for control of a coleopteran insect pest which comprises applying to the locus where a coleopteran insect may feed a synergistically effective amount of at least one coleopteran-active toxin and at least one lepidopteran-active toxin. Further provided is a method for the enhanced protection of a transgenic crop from damage caused by coleopteran insect attack and infestation. DEFINITIONS [0009] For clarity, certain terms used in the specification are defined and presented as follows: [0010] "Activity" means the protein toxins and combinations of such toxins function as orally active insect control agents, have a toxic effect, or are able to disrupt or deter insect feeding, which may or may not cause death of the insect. When a composition of the invention is delivered to the insect, the result is typically death of the insect, or the insect does not feed upon the source that makes the composition available to the insect. Such a composition may be a transgenic plant expressing the toxin combinations of the invention. One example is a transgenic corn plant expressing a modified Cry3A protein and a CrylAb protein, which causes a synergistic activity against corn rootworm feeding on the transgenic corn plant. [0011] To "control" or "controlling" insects means to inhibit, through a toxic effect, the ability of insect pests to survive, grow, feed, and/or reproduce, or to limit insect-related damage or loss in crop plants. To "control" insects may or may not mean killing the insects, although it preferably means killing the insects. [0012] As used herein, the term "corn" means Zea mays or maize and includes all plant varieties that can be bred with corn, including wild maize species. 3 WO 2012/006271 PCT/US2011/042932 [00131 To "deliver" or "delivering" a composition or toxin means that the composition or toxin comes in contact with an insect, resulting in a toxic effect and control of the insect. The composition or toxin can be delivered in many recognized ways, e.g., orally by ingestion by the insect via transgenic plant expression, formulated protein composition(s), sprayable protein composition(s), a bait matrix, or any other art-recognized toxin delivery system. [00141 "Effective insect-controlling amount" means that concentration of toxin or toxins that inhibits, through a toxic effect, the ability of insects to survive, grow, feed and/or reproduce, or to limit insect-related damage or loss in crop plants. "Effective insect-controlling amount" may or may not mean killing the insects, although it preferably means killing the insects. [0015] "Expression cassette" as used herein means a nucleic acid sequence capable of directing expression of a particular nucleic acid sequence in an appropriate host cell, comprising a promoter operably linked to the nucleic acid sequence of interest which is operably linked to termination signals. It also typically comprises sequences required for proper translation of the nucleic acid sequence. The expression cassette comprising the nucleic acid sequence of interest may be chimeric, meaning that at least one of its components is heterologous with respect to at least one of its other components. The expression cassette may also be one that is naturally occurring but has been obtained in a recombinant form useful for heterologous expression. Typically, however, the expression cassette is heterologous with respect to the host, i.e., the particular nucleic acid sequence of the expression cassette does not occur naturally in the host cell and must have been introduced into the host cell or an ancestor of the host cell by a transformation event. The expression of the nucleic acid sequence in the expression cassette may be under the control of a constitutive promoter or of an inducible promoter that initiates transcription only when the host cell is exposed to some particular external stimulus. In the case of a multicellular organism, such as a plant, the promoter can also be specific to a particular tissue, or organ, or stage of development. [0016] "Event MIR604" or "MIR604 event" or "MIR604" means a transgenic corn event, disclosed in US Patent 7,361,813 (incorporated herein by reference) that has incorporated into its genome a cry3AO55 transgene, disclosed in US Patent 7,230,167, and apmi transgene, disclosed in US Patent No. 5,767,378. Therefore, MIR604 comprises a first transgene encoding a Cry3AO55 insecticidal protein (modified Cry3A or mCry3A), useful in 4 WO 2012/006271 PCT/US2011/042932 controlling corn rootworm (Diabrotica spp.) insect pests, and a second transgene encoding a phosphomannose isomerase enzyme (PMI), useful as a selectable marker, which allows a corn plant to utilize mannose as a carbon source. [0017] "Event MIR162" or "MIR162 event" or "MIR162 event" means the transgenic corn event disclosed in International Publication No. WO 07/142840 that has incorporated into its genome a vip3A a20 transgene and apmi transgene. Therefore, MIR162 comprises a first transgene encoding a Vip3Aa20 insecticidal protein, useful in controlling lepidopteran insect pests, and a second transgene encoding a phosphomannose isomerase enzyme (PMI), useful as a selectable marker, which allows a corn plant to utilize mannose as a carbon source. [0018] "Event Btl 1" or "Btl 1 event" or "Btl 1" means the transgenic corn event disclosed in US Patent 6,114,608 (incorporated herein by reference) that has incorporated into its genome a cry1A b transgene and a pat transgene. Therefore, Bt 11 comprises a first transgene encoding a Cry 1Ab insecticidal protein, useful in controlling lepidopteran insect pests, and a second transgene encoding a PAT enzyme, useful as a selectable marker, which confers on the corn plant herbicide tolerance. [00191 A "gene" is a defined region that is located within a genome and that, besides the aforementioned coding nucleic acid sequence, comprises other, primarily regulatory, nucleic acid sequences responsible for the control of the expression, that is to say the transcription and translation, of the coding portion. A gene may also comprise other 5' and 3' untranslated sequences and termination sequences. Further elements that may be present are, for example, introns. [0020] "Gene of interest" refers to any gene which, when transferred to a plant, confers upon the plant a desired trait such as antibiotic resistance, virus resistance, insect resistance, disease resistance, or resistance to other pests, herbicide tolerance, improved nutritional value, improved performance in an industrial process or altered reproductive capability. The "gene of interest" may also be one that is transferred to plants for the production of commercially valuable enzymes or metabolites in the plant. [0021] As used herein, the term "grower" means a person or entity that is engaged in agriculture, raising living organisms, such as crop plants, for food or raw materials. 5 WO 2012/006271 PCT/US2011/042932 [0022] A "heterologous" nucleic acid sequence is a nucleic acid sequence not naturally associated with a host cell into which it is introduced, including non- naturally occurring multiple copies of a naturally occurring nucleic acid sequence. [0023] A "homologous" nucleic acid sequence is a nucleic acid sequence naturally associated with a host cell into which it is introduced. [0024] "Insecticidal" is defined as a toxic biological activity capable of controlling insects, preferably by killing them. [0025] An "isolated" nucleic acid molecule or an isolated protein is a nucleic acid molecule or protein that, by the hand of man, exists apart from its native environment and is therefore not a product of nature. An isolated nucleic acid molecule or protein may exist in a purified form or may exist in a non-native environment such as, for example, a recombinant host cell. For example, a native Cry protein in Bacillus thuringiensis is not isolated, but that same Cry protein in a transgenic plant is isolated. [0026] "Modified Cry3A (mCry3A)" means a gene or protein disclosed in US Patent No. 7,030,295, published April 18, 2006, which is herein incorporated by reference, useful in controlling corn rootworm (Diabrotica spp.) insect pests. [0027] A "nucleic acid molecule" or "nucleic acid sequence" is a linear segment of single- or double-stranded DNA or RNA that can be isolated from any source. In the context of the present invention, the nucleic acid molecule or nucleic acid sequence is preferably a segment of DNA. [0028] A "plant" is any plant at any stage of development, particularly a seed plant. [0029] A "plant cell" is a structural and physiological unit of a plant, comprising a protoplast and a cell wall. The plant cell may be in the form of an isolated single cell or a cultured cell, or as a part of a higher organized unit such as, for example, plant tissue, a plant organ, or a whole plant. [00301 "Plant cell culture" means cultures of plant units such as, for example, protoplasts, cell culture cells, cells in plant tissues, pollen, pollen tubes, ovules, embryo sacs, zygotes and embryos at various stages of development. [0031] "Plant material" refers to leaves, stems, roots, flowers or flower parts, fruits, pollen, egg cells, zygotes, seeds, cuttings, cell or tissue cultures, or any other part or product of a plant. 6 WO 2012/006271 PCT/US2011/042932 [00321 A "plant organ" is a distinct and visibly structured and differentiated part of a plant such as a root, stem, leaf, flower bud, or embryo. [0033] "Plant tissue" as used herein means a group of plant cells organized into a structural and functional unit. Any tissue of a plant in planta or in culture is included. This term includes, but is not limited to, whole plants, plant organs, plant seeds, tissue culture and any groups of plant cells organized into structural and/or functional units. The use of this term in conjunction with, or in the absence of, any specific type of plant tissue as listed above or otherwise embraced by this definition is not intended to be exclusive of any other type of plant tissue. [0034] "Transformation" is a process for introducing heterologous nucleic acid into a host cell or organism. In particular, "transformation" means the stable integration of a DNA molecule into the genome of an organism of interest. [0035] "Transformed / transgenic / recombinant" refer to a host organism such as a bacterium or a plant into which a heterologous nucleic acid molecule has been introduced. The nucleic acid molecule can be stably integrated into the genome of the host or the nucleic acid molecule can also be present as an extrachromosomal molecule. Such an extrachromosomal molecule can be auto-replicating. Transformed cells, tissues, or plants are understood to encompass not only the end product of a transformation process, but also transgenic progeny thereof. A "non-transformed", "non-transgenic", or "non- recombinant" host refers to a wild type organism, e.g., a bacterium or plant, which does not contain the heterologous nucleic acid molecule. [0036] The "Vip3" class of proteins comprises, for example, Vip3Aa, Vip3Ab, Vip3Ac, Vip3Ad, Vip3Ae, VipAf, Vip3Ag, Vip3Ba, and Vip3Bb, and their homologues. "Homologue" means that the indicated protein or polypeptide bears a defined relationship to other members of the Vip3 class of proteins. "Vip3Aa2O" (GeneBank Accession No. DQ539888) is a Vip3 homologue unique to event MIR162. It was generated by spontaneous mutations introduced into the maize-optimized vip3Aa19 gene (GeneBank Accession No. DQ539887) during the plant transformation process. [0037] The nomenclature used herein for DNA bases and amino acids is as set forth in 37 C.F.R. § 1.822. 7 WO 2012/006271 PCT/US2011/042932 DETAILED DESCRIPTION [0038] This invention relates to compositions and methods for synergistic coleopteran insect pest control which comprises applying to the locus where a coleopteran insect may feed a synergistically effective composition comprising at least one coleopteran-active toxin and at least one lepidopteran-active toxin. It is well known in the art that if two unrelated proteins are not toxic separately, they will not be toxic when combined. It is also known that combining a protein with no activity against a target pest with a protein active against that target pest, the non-active protein will not increase the activity of the already active protein. [0039] According to the invention, it has now unexpectedly been found that the application of a combination of at least one coleopteran-active protein toxin and at least one lepidopteran-active protein toxin demonstrates a significant synergistic effect (i.e. the resultant coleopteran insect control is much greater than that which could be predicted from the coleopteran insect control of the coleopteran-active toxin used alone). This synergistic effect enables a commercially useful level of coleopteran insect control and helps mitigate the development of insect resistance to a single toxin. [0040] In one embodiment, the present invention encompasses a method of controlling a coleopteran insect pest, which method comprises delivering to a coleopteran pest or environment thereof a composition comprising at least one coleopteran-active protein and at least one lepidopteran-active protein, wherein the composition controls the coleopteran pest to a greater degree than would be expected due to any individual coleopteran-active protein comprised therein alone. [0041] In one aspect of this embodiment, the coleopteran-active protein is a modified Cry3A and the lepidopteran-active protein is a Cryl protein or a Vip3 protein. In yet another embodiment, the Cryl protein is CrylAb. Examples of a CrylAb protein have the following GenBank Accession numbers: CrylAbl (AAA22330), CrylAb2 (AAA22613), CrylAb3 (AAA22561), CrylAb4 (BAA00071) , CrylAb5 (CAA28405), CrylAb6 (AAA22420), CrylAb7 (CAA31620), CrylAb8 (AAA22551), CrylAb9 (CAA38701), CrylAblO (A29125), CrylAb11 (112419), CrylAbl2 (AAC64003), CrylAbl3 (AAN76494), CrylAbl4 (AAG16877), CrylAbl5 (AA013302), CrylAbl6 (AAK55546), CrylAbl7 (AAT46415), CrylAbl8 (AAQ88259), CrylAbl9 (AAW31761), CrylAb20 (ABB72460), 8 WO 2012/006271 PCT/US2011/042932 CrylAb21 (ABS18384), CrylAb22 (ABW87320), CrylAb23 (HQ439777), CrylAb24 (HQ439778), CrylAb25 (HQ685122) and CrylAb26 (HQ847729). In still another embodiment, the CrylAb protein is that protein comprised in the Btl 1 event and disclosed in US Patent 6,114,608. The skilled person will recognize that other coleopteran-active Cry proteins are useful in the present invention including, but not limited to Cry3B, Cry8 and Cry34/Cry3 5. The skilled person will also recognize that other lepidopteran-active proteins are useful in the present invention including, but not limited to, CrylE, Cry1F, Cry1G, Cry 1H, Cry 1J, Cry2A and Cry9. The Vip3 protein can be selected from the group consisting of Vip3A, Vip3B and Vip3C. In one embodiment, the Vip3A protein is Vip3Aa2O. However, the skilled person will recognize that other Vip3 proteins are useful in the present invention. [0042] In yet another aspect of this embodiment, the coleopteran pest is a Colorado potato beetle or a corn rootworm. In another embodiment, the corn rootworm is a western corn rootworm, a northern corn rootworm, a southern corn rootworm or a Mexican corn rootworm. [0043] In another embodiment of the encompassed method, the composition is a transgenic plant expressing the coleopteran-active protein and the lepidopteran-active protein. In one aspect the transgenic plant is selected from the group consisting of soybean, cotton, rapeseed, canola, vegetables, sunflower, tobacco, tomato, sugar cane, rice, wheat, corn, rye oat, barley, turf grass and a forage crop. In another aspect, the transgenic plant is a transgenic corn plant. In yet another aspect, the transgenic corn plant is a breeding stack comprising the transgenic corn events MIR604 and Btl 1. In another aspect, the transgenic corn plant is a breeding stack comprising the transgenic corn events MIR604, Btl land MIRI 62. [0044] In another embodiment, the invention encompasses a method of controlling a corn rootworm pest, which method comprises delivering to the corn rootworm pest or an environment thereof a composition comprising a modified Cry3A (mCry3A) protein and a Cry 1Ab protein, wherein the composition controls the corn rootworm pest to a greater degree than would be expected due to the mCry3A protein alone. [0045] In another embodiment, the composition is a transgenic corn plant. In yet another embodiment, the transgenic corn plant comprises the MIR604 event and the Btl 1 event. [0046] In one embodiment, the invention encompasses a coleopteran controlling composition comprising at least one coleopteran-active protein and at least one lepidopteran-active 9 WO 2012/006271 PCT/US2011/042932 protein, wherein the composition controls a coleopteran pest to a greater degree than would be expected due to any individual coleopteran-active protein comprised therein alone. [0047] In one aspect of this embodiment, the coleopteran-active protein is a modified Cry3A and the lepidopteran-active protein is a Cryl protein or a Vip3 protein. In another embodiment, the Cryl protein is CrylAb. Examples of a CrylAb protein have the following GenBank Accession numbers: CrylAbl (AAA22330), CrylAb2 (AAA22613), CrylAb3 (AAA22561), CrylAb4 (BAA00071) , CrylAb5 (CAA28405), CrylAb6 (AAA22420), CrylAb7 (CAA31620), CrylAb8 (AAA22551), CrylAb9 (CAA38701), CrylAblO (A29125), CrylAb11 (112419), CrylAbl2 (AAC64003), CrylAbl3 (AAN76494), CrylAbl4 (AAG16877), CrylAbl5 (AA013302), CrylAbl6 (AAK55546), CrylAbl7 (AAT46415), CrylAbl8 (AAQ88259), CrylAbl9 (AAW31761), CrylAb20 (ABB72460), CrylAb2l (ABS18384), CrylAb22 (ABW87320), CrylAb23 (HQ439777), CrylAb24 (HQ439778), CrylAb25 (HQ685122) and CrylAb26 (HQ847729). In still another embodiment, the Cry 1 Ab protein is that protein comprised in the Bt 11 event and disclosed in US Patent 6,114,608. The skilled person will recognize that other coleopteran-active Cry proteins are useful in the present invention including, but not limited to Cry3B, Cry8 and Cry34/Cry35. The skilled person will also recognize that other lepidopteran-active proteins are useful in the present invention including, but not limited to, Cry1E, Cry1F, CryIG, CrylH, CrylJ, Cry2A and Cry9. The Vip3 protein can be selected from the group consisting of Vip3A, Vip3B and Vip3C. In one embodiment, the Vip3A protein is Vip3Aa2O. However, the skilled person will recognize that other Vip3 proteins are useful in the present invention. [00481 In yet another aspect of this embodiment, the coleopteran pest is a Colorado potato beetle or a corn rootworm. In another embodiment, the corn rootworm is a western corn rootworm, a northern corn rootworm, a southern corn rootworm or a Mexican corn rootworm. [0049] In still another embodiment, the composition is a transgenic plant expressing the coleopteran-active protein and the lepidopteran-active protein. In one aspect the transgenic plant is selected from the group consisting of soybean, cotton, rapeseed, canola, vegetables, sunflower, tobacco, tomato, sugar cane, rice, wheat, corn, rye oat, barley, turf grass and a forage crop. In another aspect, the transgenic plant is a transgenic corn plant. In another aspect, the transgenic plant is a transgenic corn plant. In another aspect, the transgenic corn 10 WO 2012/006271 PCT/US2011/042932 plant is a breeding stack comprising the transgenic corn events MIR604 and Btl 1. In another aspect, the transgenic corn plant is a breeding stack comprising the transgenic corn events MIR604, Btl 1 and MIR1 62. [0050] In yet another embodiment, the invention encompasses a method of providing a grower with a means of controlling a coleopteran insect pest population comprising supplying or selling to the grower transgenic seed comprising a nucleic acid that encodes at least one coleopteran-active protein and at least one lepidopteran-active protein, wherein transgenic plants grown from said seed control a coleopteran pest to a greater degree than would be expected due to any individual coleopteran-active protein comprised therein alone. [00511 In another embodiment, the coleopteran-active protein is a modified Cry3A and the lepidopteran-active protein is a Cryl protein or a Vip3 protein. In yet another embodiment, the Cryl protein is CrylAb. Examples of a CrylAb protein have the following GenBank Accession numbers: CrylAbl (AAA22330), CrylAb2 (AAA22613), CrylAb3 (AAA22561), CrylAb4 (BAA00071), CrylAb5 (CAA28405), CrylAb6 (AAA22420), CrylAb7 (CAA31620), CrylAb8 (AAA22551), CrylAb9 (CAA38701), CrylAblO (A29125), CrylAb11 (112419), Cry1Abl2 (AAC64003), Cry1Abl3 (AAN76494), Cry1Abl4 (AAG16877), CrylAbl5 (AA013302), CrylAbl6 (AAK55546), CrylAbl7 (AAT46415), CrylAbl8 (AAQ88259), CrylAbl9 (AAW31761), CrylAb20 (ABB72460), CrylAb2l (ABS18384), CrylAb22 (ABW87320), CrylAb23 (HQ439777), CrylAb24 (HQ439778), CrylAb25 (HQ685122) and CrylAb26 (HQ847729). In still another embodiment, the Cry lAb protein is that protein comprised in the Btl 1 event and disclosed in US Patent 6,114,608. The skilled person will recognize that other coleopteran-active Cry proteins are useful in the present invention including, but not limited to Cry3B, Cry8 and Cry34/Cry35. The skilled person will also recognize that other lepidopteran-active proteins are useful in the present invention including, but not limited to, Cry1E, Cry1F, Cry1G, Cry1H, Cry1J, Cry2A and Cry9. The Vip3 protein can be selected from the group consisting of Vip3A, Vip3B and Vip3C. In one embodiment, the Vip3A protein is Vip3Aa2O. However, the skilled person will recognize that other Vip3 proteins are useful in the present invention. [00521 In still another embodiment, the coleopteran pest is a Colorado potato beetle or a corn rootworm. In one embodiment, the corn rootworm is a western corn rootworm, a northern corn rootworm, a southern corn rootworm or a Mexican corn rootworm. 11 WO 2012/006271 PCT/US2011/042932 [0053] In another embodiment, the transgenic plant seed and plant is selected from the group consisting of soybean, cotton, rapeseed, canola, vegetables, sunflower, tobacco, tomato, sugar cane, rice, wheat, corn, rye oat, barley, turf grass and a forage crop. In another embodiment, the transgenic plant seed and plant is a transgenic corn seed and plant. [00541 The co-expression of at least one coleopteran-active protein and at least one lepidopteran-active protein in the same transgenic plant can be achieved by genetically engineering a plant to contain and express all the genes necessary in a so called molecular stack. Alternatively, a plant, Parent 1, can be genetically engineered for the expression of certain genes encoding insecticidal proteins of the invention. A second plant, Parent 2, can be genetically engineered for the expression of certain other genes encoding insecticidal proteins of the invention. By crossing Parent 1 with Parent 2, progeny plants are obtained which express all the genes introduced into Parents 1 and 2, designated herein as a "breeding stack." Such a breeding stack to create a composition of the invention can be achieved by crossing a corn plant comprising the MIR604 event with a corn plant comprising the Btl 1 event. Thus, the progeny of the breeding stack comprise a mCry3A protein and a CrylAb protein disclosed herein to provide a synergistic control of coleopteran insect pests. [0055] Compositions of the invention, for example, transgenic plant seed, can also be treated with an insecticidal seed coating as described in U. S. Patent Nos. 5,849,320 and 5,876,739, herein incorporated by reference. Where both the insecticidal seed coating and the transgenic seed of the invention are active against the same target insect, the combination is useful (i) in a method for further enhancing activity of the synergistic composition of the invention against the target insect and (ii) in a method for preventing development of resistance to the composition of the invention by providing yet another mechanism of action against the target insect. Thus, the invention provides a method of enhancing activity against or preventing development of resistance in a target insect, for example corn rootworm, comprising applying an insecticidal seed coating to a transgenic seed of the invention. Such chemical treatments may include insecticides, fungicides or nematicides. Examples of such insecticides include, without limitation, dinotefuran, such as thiamethoxam, imidacloprid, acetamiprid, nitenpyram, nidinotefuran, chlorfenapyr, tebufenpyrad, tebufenozide, methoxyfenozide, halofenozide, triazamate, avermectin, spinosad, fiprinol, acephate, fenamiphos, diazinon, chlorpyrifos, chlorpyrifon-methyl, malathion, carbaryl, aldicarb, 12 C:\NRPortbl\DCC\GRS\4812049_1.DOC-4 3 2013 carbofuran, thiodicarb, and oxamyl. Even where the insecticidal seed coating is active against a different insect, the insecticidal seed coating is useful to expand the range of insect control, for example by adding an insecticidal seed coating that has activity against lepidopteran insects to the transgenic seed of the invention, which has activity against coleopteran insects, the coated transgenic seed produced controls both lepidopteran and coleopteran insect pests. EXAMPLES [0056] The invention will be further described by reference to the following detailed examples. These examples are provided for the purposes of illustration only, and are not intended to be limiting unless otherwise specified. Standard recombinant DNA and molecular cloning techniques used here are well known in the art and are described by J. Sambrook, et al., Molecular Cloning: A Laboratory Manual, 3d Ed., Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press (2001); by T.J. Silhavy, M.L. Berman, and L.W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984) and by Ausubel, F.M. et al., Current Protocols in Molecular Biology, New York, John Wiley and Sons Inc., (1988), Reiter, et al., Methods in Arabidopsis Research, World Scientific Press (1992), and Schultz et al., Plant Molecular Biology Manual, Kluwer Academic Publishers (1998). Example 1. Interaction between toxins against Colorado potato beetle [0057] In this example the effects of mCry3A on the toxicity of CrylAb, and the effects of Cry lAb on the toxicity ofmCry3A, are measured with bioassays testing the insecticidal proteins alone and in combination. Event Btl Icorn and Event MIR604 corn express the insecticidal proteins CrylAb and modified Cry3A (mCry3A), respectively. CrylAb is active against certain Lepidoptera, whereas mCry3A is active against some species of Coleoptera. In the United States (US), the main use of Btl1 corn is for control of European com borer (Ostrinia nubilalis; ECB) and the principal targets of MIR604 maize are western com rootworm (Diabrotica virgifera virgifera; WCR) and northern corn rootworm (Diabrotica longicornis barberi; NCR). Through conventional breeding stacks of Btl1 and MIR604 13 WO 2012/006271 PCT/US2011/042932 plants, stacked Bt 11 x MIR604 maize hybrids producing both Cry 1Ab and mCry3A were created. These maize hybrids provide control of ECB as well as WCR and NCR. [0058] The indicator organisms used are first-instar ECB, which is highly sensitive to CrylAb, and first-instar Colorado potato beetle (Leptinotarsa decemlineata; CPB), which is highly sensitive to mCry3A. ECB is not sensitive to mCry3A, and CPB is insensitive to CrylAb. Although CPB is not a target pest of MIR604 or Btl 1 x MIR604 maize, it is more amenable to laboratory testing than the rootworm species targeted by mCry3A. Both ECB and CPB larvae are readily bioassayed using standard artificial diets under the same laboratory conditions. Because first instars of these species are highly susceptible to either CrylAb or mCry3A, the ability to detect many significant changes in the toxicity of either protein is maximized. In each combinatorial bioassay, each sensitive species is exposed to a high and a low concentration of the toxin, represented by the LC70 and LC30, respectively, in combination with a high concentration of the non-toxin, represented by the LC90 to the corresponding sensitive species. [00591 Various experimental designs are available for testing interactions between toxins. The design depends on the model used to predict the effects of mixtures of toxins, without interaction, from effects of the compounds alone; an interaction is detected when observed effects of the mixture differ from predictions of the model. When toxins have similar effects, so that one compound can be substituted as a constant proportion of the other, the null model is called similar joint action. When this model applies, a test for interaction determines a dose response for a fixed ratio of the compounds (e.g., Tabashnik, 1992). When toxins act independently (different modes of action), the best model is independent joint action, and a test for interaction examines the effects of varying proportions of the compounds in a factorial design (e.g., Tajima et al., 2002). Comprehensive data sets for CrylAb and mCry3A indicate that organisms sensitive to one protein will not be sensitive to the other protein; in other words, only one compound is toxic to a particular organism and the null hypothesis is that the mixture has no additional effect. In these situations, an interaction is shown by a difference between the toxicity of protein A alone and its toxicity in the presence of protein B. For an organism sensitive to protein A, in effect there is no dose-response to protein B, and hence there is no reason to expect the concentration of protein B to affect the toxicity of protein A. Therefore, testing the effect of protein B at a fixed concentration is a simple and 14 WO 2012/006271 PCT/US2011/042932 effective method to test for any interaction. This method most closely resembles the "simple empirical approach" described by Tabashnik (1992). [0060] Interaction between the two insecticidal proteins is detected as a statistically significant difference between the mortality observed with the single toxic protein and the mortality observed when the second protein is added in combination with the toxic protein. First-instar ECB are exposed to Cry 1Ab at the LC30 and LC70, alone and in combination with a high concentration of mCry3A, corresponding to the LC90 for first-instar CPB. Correspondingly, first-instar CPB are exposed to mCry3A at the LC30 and LC70 alone and in combination with a high concentration of CrylAb, corresponding to the LC90 for first instar ECB. [00611 Exposing the sensitive species at both their LC30 and LC70 allows evaluation of potential interaction with the second protein at two distinct points in the dose-response curve. Exposure to the second protein at a concentration that is highly toxic (LC90) to the sensitive species provides a sufficiently high exposure to detect any biologically relevant toxicity if there is interaction between the two proteins. [0062] The sources of CrylAb and mCry3A used in the bioassays are test substances produced by over-expressing each protein in recombinant E. coli followed by purification. Cry 1Ab and mCry3A as contained in these test substances are substantially equivalent to the insecticidal proteins as expressed in Btl 1 and MIR604 transgenic corn plants, respectively. The use of purified proteins produced in microbes is preferable to using plant-derived preparations of CrylAb and mCry3A. The relatively higher purity of the microbially derived test substances allowed for more precise toxicity determinations, without interference from plant substances. These plant substances might not be present in equal quantities in both Btl 1- and MIR604-derived materials, as well as in control materials, and may confound interpretation of the bioassay results. [0063] Production of CrylAb test substance: The CrylAb test substance is determined to contain approximately 127 ig CrylAb/ml test substance (0.0127% w/v). After preparation, the test substance is stored at approximately 4'C. The trypsin-truncated Cryl Ab in the test substance corresponds approximately to the truncated Cry1Ab encoded in Btl 1 corn. The truncated Cry 1 Ab protein encoded in Bt1 1 corn represents the first 615 N-terminal amino acids of the full-length native Cry 1Ab protein from B. thuringiensis subsp. kurstaki. By 15 WO 2012/006271 PCT/US2011/042932 comparison, the predominant form of trypsin-truncated CrylAb in the test substance is a 587 amino acid protein, representing the same truncated Cry 1 Ab protein present in Bt 11 corn, minus the first 28 N-terminal amino acids (Kramer, 2006). Trypsinization of the Cry1Ab in Btl 1 corn removes these 28 N-terminal amino acids (which are not required for insecticidal activity), and further demonstrates the substantial equivalence of E. coli-produced trypsin truncated Cry1Ab and the truncated Cry1Ab produced in Bt 11, as measured by SDSPAGE, Western blot analysis, N-terminal sequencing, peptide mapping, biological activity against neonate ECB larvae, and absence of detectable glycosylation. Therefore, the truncated Cry 1 Ab protein present in the test substance can be considered substantially equivalent to the truncated Cry 1Ab protein encoded in Bt 11 maize. [0064] Production of mCry3A test substance: The mCry3A test substance is determined to contain approximately 90% mCry3A protein by weight, to have bioactivity against a sensitive coleopteran species and is shown to be substantially equivalent to mCry3A as produced in Event MIR604 corn, as assessed by various biochemical and functional parameters. After preparation, the mCry3Atest substance is stored at approximately -20'C. [00651 Estimation of LC30, LC70 and LC90 for ECB Does-Response to CrylAb: The bioactivity of the Cry lAb is assessed in insect feeding assays using first-instar ECB larvae in accordance with standard methods known in the art. Briefly, the bioassays are conducted in Costar 24-well plates (Fisher Scientific, Cat. # PD 10-047 -05). The test solutions are prepared by diluting the liquid Cry lAb test substance in 0.6 UM ammonium carbonate buffer. One hundred d of each dilution are added to 100 pl ECB diet (General Lepidopteran Diet from BioServe, Inc.; Frenchtown, NJ, USA) and mixed thoroughly. The ECB insect diet is prepared in accordance methods known in the art. Each well contains 200 gl insect diet containing concentrations of Cry 1Ab ranging from 3 to 372 ng/ml diet. Each treatment consists of 24 replicate wells containing one ECB larva/well. The plates are maintained at ambient laboratory conditions with regard to temperature, lighting and relative humidity. To control bias, the larvae are randomly allocated to treatment groups. As controls, larvae are exposed to insect diet without test substance (diet alone); insect diet treated with the same buffer concentration used in applying the highest test substance concentration to the diet (100 pl of ca. 0.6 pM 50 mM NH4HCO3, pH 9.25, buffer/100 ml diet); and diet treated with a solution of heat-inactivated Cry1Ab test substance (30 minutes at 100'C) at a concentration 16 WO 2012/006271 PCT/US2011/042932 equivalent to the highest test substance concentration (372 ng Cry 1Ab/ml diet) used in the bioassay. The heat-inactivated protein treatment serves as a control for the potential effects of added protein in the insect diet and impurities (i.e., non-CrylAb components) in the test substance. Mortality is assessed at around 144 hrs. [00661 The US EPA Probit Analysis Program, version 1.5, US EPA, 1992, is used to determine LC50 and LC90 values; in addition, the slope equation for the regression of the log-dose pro bit relationship was used to determine the LC30 and LC70 values in conjunction with a normal distribution probit table (Geigy Scientific Tables, Lentner, 1982). Other probit programs can also be used. [00671 Estimation of LC30, LC70 and LC90 for CPB Dose-Response to mCry3A: Using the mCry3A test substance, the LC30, LC70 and LC90 of mCry3A to first-instar CPB is determined in the same manner as that described above for ECB using standard methods known in the art. The test solutions are prepared by dissolving the lyophilized test substance in MilliQ@ water. One hundred pg of each dilution are added to 100 ptg CPB diet (BioServe, Inc., Frenchtown, New Jersey, USA) and mixed thoroughly. The CPB insect diet is prepared using methods known in the art. Each well contains 200 [d insect diet with concentrations of mCry3A ranging from 0.01 to 5 pg/ml diet. As controls, larvae are exposed to insect diet without test substance added (diet alone), insect diet treated with the same volume of MilliQ water used in applying the test substance solution to the diet alone, and diet treated with a solution of heat-inactivated mCry3A protein from the test substance (30 minutes at 100'C) at a concentration equivalent to the highest test substance concentration (5 pg mCry3A/ml diet) used in the bioassay. Mortality is assessed at 96 hrs. [0068] Evaluation of Effect of mCry3A on CrylAb Toxicity: The effect of mCry3A on the toxicity of CrylAb is measured by exposing first-instar ECB to the LC30 (equivalent to 27 ng Cry 1 Ab/ml diet) and LC70 (equivalent to 70 ng Cry 1 Ab/ml diet) of Cry 1 Ab and comparing the mortality in the presence and absence of mCry3A. The concentration of mCry3A corresponding to the CPB LC90 (equivalent to 2.4 ptg mCry3A/ml diet) is determined as described above. [0069] The interaction bioassay is performed using the same culture procedures and conditions described above, except that triplicate 24-well culture plates are used for each treatment. Each treatment plate contains 24 larvae, for a total of 72 larvae per treatment. As 17 WO 2012/006271 PCT/US2011/042932 controls, larvae are exposed to insect diet without test substance (diet alone); insect diet treated with the same buffer concentration used in applying the highest test substance concentration to the diet (100 pl of ca. 0.6 tM 50 mM NH4HC03, pH 9.25, buffer/100 ml diet); diet treated with a solution of heat-inactivated Cry1Ab (30 minutes at 100 C) at a concentration equivalent to the highest Cry1Ab concentration (372 ng Cryl Ab/ml diet) used in the bioassay; and mCry3A dosed at 2.4 tg/ml diet, corresponding to the LC90 of mCry3A against CPB. CPB diet treated with the LC70 (equivalent to 1.4 tg mCry3A/ml diet) of mCry3A against CPB is used as concurrent positive control to confirm the insecticidal activity of mCry3A. Mortality is assessed after approximately 144 and 168 hours. The entire interaction bioassay with ECB is conducted twice. [0070] Evaluation of Effect of Cryl Ab on mCry3A Toxicity: The effect of Cry1Ab on the toxicity of mCry3A is measured by exposing first-instar CPB to the LC30 (equivalent to 0.62 tg mCry3A/ml diet) and LC70 (equivalent to 1.35 [g mCry3A/ml diet) concentrations of mCry3A and comparing the mortality in the presence and absence of Cry1Ab. The concentration of Cry1Ab is the ECB LC90 (equivalent to 142 ng Cry1Ab/ml diet). The number of replicate treatments and the analysis of CPB mortality data are the same as described above. 100711 The interaction bioassays are performed using the same culture procedures and conditions described above, except that triplicate 24-well culture plates are used for each treatment. Each treatment plate contains 24 larvae, for a total of 72 larvae per treatment. As controls, larvae are exposed to insect diet without test substance (diet alone), insect diet treated with the same volume of MilliQ water used in applying the test substance solution to the diet alone, diet treated with a solution of heat-inactivated Cry1Ab (30 minutes at 100*C) at a concentration equivalent to the highest mCry3A concentration (5 pg mCry3A/ml diet) used in the bioassay, and Cry lAb dosed at 142 ng/ml diet corresponding to the LC90 of Cry1Ab against ECB. ECB diet treated with the LC70 concentration (equivalent to 70 ng Cry1Ab/ml diet) of Cry1Ab against ECB is used as concurrent positive control to confirm the insecticidal activity of Cry lAb used in the combinatorial bioassay. Mortality is assessed after approximately 72 and 96 hours. The entire interaction bioassay with ECB is conducted twice. 10072] Statistical Methods: In each study, several criteria have to be met for the experimental design and data analysis described below to be a valid and effective test for an interaction 18 WO 2012/006271 PCT/US2011/042932 between the proteins: (1) There is no effect of the buffer used to dissolve the proteins; (2) There is no effect of the addition of protein per se; or (3) The "non-toxin" is not toxic to the insensitive bioassay species at the concentrations used in this experiment. For both the ECB and CPB experiments, these criteria are met. [0073] Once mortality is observed in the bioassays, mortality is recorded each day until there is approximately 30% mortality in the LC30 treatment and 70% mortality in the LC70 treatment. Data from each of the sampling occasions within each protein interaction study are analyzed separately. At each sampling, separate analyses are performed for each assay alone and for the combined data from both assays. [0074] At each sampling in each bioassay, the response analyzed is the arcsine square-root transformed proportion of dead larvae per replicate. The effects of the various treatments are tested by ANOVA. For both experiments (ECB and CPB), the two assays are analyzed separately and combined (if valid). A crucial assumption of ANOVA is that there is homogeneity of variance among the treatments and the residuals are normally distributed. This is unlikely to be true if the negative control treatments are included, as the proportion of dead larvae is zero in many replicates. This is a particular problem for ANOVA of arcsine square-root-transformed data. Therefore the negative control data are excluded from the analysis, as their validation of the assumptions of the method is clear without statistical analysis. For the assays analyzed separately, ANOVA with an effect for treatment is performed. Levene's test (SAS, 2002-2003) is used to check the assumption of homogeneity of variance within each of the four treatments and Shapiro-Wilks' test (SAS, 2002-2003) is used to check the assumption of normally distributed residuals. For analysis of the combined assays, ANOVA with effects for assay and treatment is performed. Shapiro-Wilks' test is used to check the assumption of normally distributed residuals. No formal test of the assumption of homogeneity of variances is performed, since Levene's test cannot be applied if there is more than one effect in the analysis of variance (SAS, 2002-2003). However, visual comparison of plots of the arcsine square-root-transformed data is used to confirm that the homogeneity of variance assumption was valid for the combined data. [0075] The factorial structure of the treatments allows three effects to be investigated: (1) The main effect of the toxic protein (Does the concentration of the toxin influence the response?); (2) The main effect of the non-toxic protein (Does the presence of the non-toxin 19 WO 2012/006271 PCT/US2011/042932 influence the response?) and (3) The interaction between the concentration of the toxin and the presence of the non-toxin (Does the effect of the non-toxin depend on the concentration of the toxin, and does the effect of toxin concentration depend on the presence of the non toxin?) [0076] The effects are investigated by setting up treatment contrasts that focuses on that effect while removing the other effects. This is achieved by examining appropriate combinations of the treatment means (a combination of treatment means is known as a contrast). Each contrast is the sum of the individual contrast coefficients multiplied by their associated treatment means. The statistical significance of each contrast can be assessed under an appropriate null hypothesis. The null hypotheses for the three items are as follows: (1) Ho: The response at low and high concentrations of the toxic protein is the same; (2) Ho: The response is the same with or without the non-toxic protein; and (3) Ho: Any effects of the toxic and non-toxic proteins act independently of each other. [0077] Each contrast is evaluated at a 5% Type I error rate using the estimate of error from the ANOVA. Treatment-contrast 2 tests whether there is synergism (or antagonism) between the two proteins. Therefore if the null hypothesis for contrast 2 is rejected then the data provide evidence of synergism (or antagonism). Further examination of the sign of any significant contrasts determines whether there is synergism or antagonism (for example, a positive contrast 2 value implies greater mortality when the non-toxic protein is present, hence synergism). [0078] The mean values and standard deviations of the combinatorial bioassays are calculated using Microsoft Excel@. RESULTS [0079] Estimation of LC30, LC70 and LC90 for CrylAb against ECB: The bioactivity estimate for CrylAb against European corn borer larvae showed an LC30 of ca. 27, LC70 of ca. 70 and an LC90 of ca. 142 ng CrylAb/ml diet after 144 hours. The negative control diets showed only low mortality, with 8% for the diet-alone treatment, 4% for the buffer-treated diet, and 4% for diet treated with inactivated Cry1Ab. [0080] Estimation of LC30, LC70 and LC90 for mCry3A against CPB: The bioactivity estimate for mCry3A against Colorado potato beetle larvae showed an LC30 of ca. 0.6, LC70 20 WO 2012/006271 PCT/US2011/042932 of ca 1.4 and an LC90 of ca. 2.4 ptg mCry3A/ml diet after 96 hours. The negative control diets showed no or only low mortality with 0% for the diet alone treatment, 8% for the water treated diet, and 4% for diet treated with inactivated mCry3A. [0081] Evaluation of Effect of mCry3A on CrylAb Toxicity: There was low mean mortality (7% or lower) on the diet alone, on the buffer-treated diet, on the heat-inactivated Cry 1Ab treated diet and the diet treated with mCry3A at the LC90 CPB (2.4 pg mCry3A/ml diet) after 168 hours. Further, there was a clear difference between the toxin-treated diets and the negative control diets. Therefore, several necessary conditions for the experimental design to be valid were demonstrated. [0082] In both assays after 144 hr, the mortalities in the LC30 and LC70 treatments (both with and without mCry3A) were statistically significantly below 30% and 70% respectively. Therefore, the assays were continued to reach the desired toxicity endpoints of the experiment. After 168 hr, the endpoints (i.e., 30% and 70% mortality in the LC30 Cry1Ab alone and LC70 CrylAb alone treatments, respectively) had been reached. The 144- hr data were considered to have power to detect effects of mCry3A on CrylAb. [0083] The results of the combined data demonstrated that the effects of CrylAb concentration and presence of mCry3A were independent at 144 hr and 168 hr (p >0.05) against European corn borer. Therefore, the effect of concentration of Cry 1 Ab could be tested by joint analysis of the data with and without mCry3A. Similarly, the effect of mCry3A could be tested by joint analysis of the LC30 and LC70 data. [0084] In the combined data, there was a statistically significant effect of concentration of CrylAb (p <0.05). At 144 hr and at 168 hr, the effect of CrylAb concentration was statistically significant in the combined data. These data indicate that ECB was responding as expected to different concentrations of Cry1Ab. [0085] In the combined data, no statistically significant effect of mCry3A on the toxicity of CrylAb was detected at 144 hr or at 168 hr (p >0.05). As no effect of mCry3A alone on ECB was detected in this study, these results provide no evidence for an interaction between Cry lAb and mCry3A in killing or controlling European corn borer. [0086] Evaluation of Effect of CrylAb on mCry3A Toxicity: For the CPB assays there was low mean mortality (4% or lower) on the diet alone, on the water-treated diet, on the heat inactivated Cry1Ab-treated diet and the diet treated with Cry1Ab at the LC90 ECB (142 ng 21 WO 2012/006271 PCT/US2011/042932 Cry 1Ab/mil diet) after 96 hours. Further, there was a clear difference between the toxin treated diets and the negative control diets. Therefore, several necessary conditions for the experimental design to be valid were demonstrated. [0087] In both CPB bioassays, after 72 hr some mortality was observed; however, the mortalities in the LC30 and LC70 treatments were statistically significantly below 30% and 70% respectively in at least one bioassay. Therefore the assays were continued to reach the desired mortality endpoints of the experiment. After 96 hr, the endpoints (i.e., 30% and 70% mortality in the LC30 mCry3A alone and LC70 mCry3A alone respectively) had been reached. The 72-hr data were considered to have power to detect effects of mCry3A on Cry 1Ab. For the separate assays and the combined data, the criteria of normality and homogeneity of variance were met at both 72 hr and 96 hr. [0088] In the combined data, the effects of mCry3A concentration and presence of CrylAb were independent at 72 hr and 96 hr (p >0.05). Therefore the effect of concentration of mCry3A could be tested by joint analysis of the data with and without Cry1Ab. Similarly, the effect of CrylAb could be tested by joint analysis of the LC30 and LC70 data. [00891 In the combined data, there was a statistically significant effect of concentration of mCry3A at 72 hr and 96 hr (p <0.05). These data indicate that CPB was responding as expected to different concentrations of mCry3A. [0090] In the combined data, no statistically significant effect of Cry 1 Ab on the toxicity of mCry3A was detected at 96 hr (p >0.05). However, in the combined data at 72 hr a statistically significant effect of CrylAb was detected (p <0.05). Therefore, an interaction between mCry3A and Cry1Ab was indicated at 72 hr in the combined data. The greater mortality in the presence of Cry 1 Ab indicates that the effect is synergism (as defined by Tabashnik, 1992) or potentiation (as defined by Haghdoost et ai., 1997). Therefore, CrylAb potentiates or synergizes the activity of mCry3A causing mCry3A to work faster against target coleopteran insects than would be expected with mCry3A alone. On a commercial scale, faster kill translates into less plant damage and less opportunity for coleopteran insect pests to develop resistance. 22 WO 2012/006271 PCT/US2011/042932 Example 2. Interaction between toxins against corn rootworm [0091] This example investigates whether there is an interaction, with regard to insecticidal activity, between a lepidopteran-active protein mixture comprising CrylAb and Vip3Aa2O ("Lep Composition"), and a coleopteran-active protein mixture comprising mCry3A ("Col Composition"). [0092] The effects of the Lep Composition on a sensitive pest species European corn borer (Ostrinia nubilalis; ECB) is investigated in the presence or absence of the Col Composition. First instar larvae are used to conduct the ECB diet incorporation bioassay. Percent ECB mortality is assessed at 120 hrs after infestation. An ECB dose-response curve with eight concentrations of the Lep Composition is established first. Two doses, ECB Dose 1 and ECB Dose 2, of the Lep Composition giving intermediate level of response are chosen from dose-response curve to conduct the lepidopteran-active and coleopteran-active protein interaction bioassay. ECB Dose 1 comprises about 25 ng CrylAb and about 12.5 ng Vip3Aa2O per ml of diet and ECB Dose 2 comprises about 50 ng CrylAb and about 25 ng Vip3Aa2O per ml of diet. Therefore, ECB Dose 2 has about 2X the amount of CrylAb and Vip3Aa2O protein as ECB Dose 1. [0093] The results of the ECB bioassay are shown in Table 1. No statistically significant increase in percent ECB mortality is detected when WCR Dose 2 of the Col Composition is present, indicating there is no interaction between the Col Composition comprising mCry3A and the Lep Composition comprising CrylAb + Vip3Aa2O based upon ECB bioassay. Table 1. Results of ECB bioassay. Treatment Percent ECB Mortality ECB Dose 1 21 ECB Dose 1 + WCR Dose 2 22 ECB Dose 2 36 ECB Dose 2 + WCR Dose 2 40 WCR Dose 2 4 Lep Buffer (Neg Check) 1 Lep + Col Buffer (Neg Check) 4 23 WO 2012/006271 PCT/US2011/042932 [00941 The effects of the Col Composition on the sensitive pest species Western corn rootworm (WCR, Diabrotica virgifera) are investigated in the presence or absence of the Lep Composition. First instar larvae are used to conduct the WCR diet incorporation bioassay. Percent WCR mortality is assessed at 120 hrs after infestation. A WCR dose-response curve with eight concentrations of the Col Composition is established first. Two doses,WCR Dose 1 and WCR Dose 2, of the Col Composition giving intermediate level of response are chosen from dose-response curve to conduct the Lep Composition and Col Composition interaction bioassay. WCR Dose 1 comprises about 50 tg mCry3A per ml of diet and WCR Dose 2 comprises about 200 pg mCry3A per ml of diet. Therefore, WCR Dose 2 has about 4X the amount of mCry3A protein as WCR Dose 1. [0095] The results of the WCB bioassay are shown in Table 2. The results indicate a higher percent WCR mortality when Dose 2 of the Lep Composition comprising Cry lAb + Vip3Aa2O is present, indicating that the combination of the Lep Composition and the Col Composition kills WCR at a greater degree than would be expected due to the Col Composition by itself. Table 2. Results of the WCR bioassay. Treatment Percent WCR Mortality WCR Dose 1 17 WCR Dose 1 + ECB Dose 2 46 WCR Dose 2 48 WCR Dose 2 + ECB Dose 2 65 ECB Dose 2 1 Col Buffer (Neg Check) 1 Col + Lep Buffer (Neg Check) 1 24 H darUIrntcOCNRPOnbIl\CUDARW37996_I.docx 7U12U 15 -25 [00961 It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof of the description will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims. [0097] All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art that this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. [00981 Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. 100991 The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

WO 2012/006271 PCT/US2011/042932 References Haghdoost, N.R., Newman, L.M. and Johnson, E.M. (1997) Multiple chemical exposures: synergism vs. individual exposure levels. Reproductive Toxicology 11: 9-27. MacIntosh, S.C., Stone, T.B., Sims, S.R., Hunst, P.L., Greenplate, J.T., Marrone, P.G., Perlak, FJ., Fischoff, D.A. and Fuchs, R.L. (1990) Specificity and efficacy of purified Bacillus thuringiensis proteins against agronomically important insects. Journal ofInvertebrate Pathology 56: 258-266. SAS Software, Version 9.1 of the SAS System for Windows. Copyright (C) 2002-2003 SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks of SAS Institute Inc, Cary, NC, USA. Tabashnik, B. (1992) Evaluation of synergism among Bacillus thuringiensis toxins. Applied and Environmental Microbiology 58: 3343-3346. Tajima, 0., Schoen, E.D., Feron, VJ. and Groten, J.P. (2002) Statistically designed experiments in a tiered approach to screen mixtures of Fusarium mycotoxins for possible interactions. Food and Chemical Toxicology 40: 685-695. US EPA (1992) EPA Probit Analysis Program version 1.5. Ecological Monitoring Research Division, Environmental Monitoring Systems Laboratory, U.S. Environmental Protection Agency, Cincinnati, OH, USA. 26

Claims (7)

1. A method of controlling a Colorado potato beetle which comprises delivering to a Colorado potato beetle or an environment thereof a composition comprising at least one coleopteran-active protein and at least one lepidopteran-active protein, wherein the composition controls the Colorado potato beetle to a greater degree than would be expected due to any individual coleopteran-active protein comprised therein alone, wherein the coleopteran-active protein is a modified Cry3A protein and wherein the lepidopteran-active protein is a Vip3 protein.

2. The method according to claim 1, wherein the Vip3 protein is a Vip3Aa protein.

3. The method according to claim 2, wherein the Vip3Aa protein is Vip3Aa2O.

4. The method according to any one of claims 1 to 3, wherein the composition is a transgenic plant expressing the coleopteran-active protein and the lepidopteran-active protein.

5. The method according to claim 4, wherein the transgenic plant is a transgenic corn plant.

6. The method according to claim 5, wherein the transgenic corn plant comprises the transgenic corn event MIRI 62.

7. The method according to claim 1, substantially as herein described and with reference to any of the Examples.